Identifying Factors of Microparticles Modified with Arginine Derivatives That Induce Phenotypic Shifts in Macrophages
Source abstract
Abstract
Macrophages are key players in the progression of many diseases, ranging from rheumatoid arthritis to cancer. Drug delivery systems have the potential not only to transport payloads to diseased tissue but also to influence cell behavior. Here, poly( N -isopropylacrylamide- co -acrylic acid) (pNIPAm- co -AAc) microparticles were modified with 14 different arginine derivatives. These particles were then incubated with interleukin-4 or lipopolysaccharide-stimulated macrophages or naïve macrophages (RAW 264.7). The phenotypic state of the macrophages was assessed by measuring arginase activity, tumor necrosis factor-α (TNF-α) secretion, and nitrite production. Partial least-squares analysis revealed material properties and descriptors that shifted the macrophage phenotype for the three cell conditions in this study. Material descriptors relating to secondary bonding were suggested to play a role in shifting phenotypes in all three macrophage culture conditions. These findings suggest that macrophage responses could be altered through drug delivery vehicles, and this method could be employed to assist in screening potential candidates.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Immune cells in cancer · Extracellular vesicles in disease · Osteoarthritis Treatment and Mechanisms
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Ames National Laboratory, Ames, Iowa 50011, United States
Funding
Division of Chemical, Bioengineering, Environmental, and Transport Systems · Roy J. Carver Charitable Trust
References (51)
Show source-provided references
1. 10.1016/j.biomaterials.2008.08.04010.1016/j.biomaterials.2008.08.040 ↗
2. 10.1016/j.biomaterials.2008.09.02610.1016/j.biomaterials.2008.09.026 ↗
3. 10.1016/j.smim.2007.11.00410.1016/j.smim.2007.11.004 ↗
4. 10.1016/j.molimm.2006.06.02010.1016/j.molimm.2006.06.020 ↗
5. 10.1021/bm501138210.1021/bm5011382 ↗
6. 10.1021/ab500106310.1021/ab5001063 ↗
7. 10.1016/j.biomaterials.2015.05.04510.1016/j.biomaterials.2015.05.045 ↗
8. 10.1016/j.biomaterials.2015.03.04210.1016/j.biomaterials.2015.03.042 ↗
9. 10.1016/j.biomaterials.2009.05.06910.1016/j.biomaterials.2009.05.069 ↗
10. 10.1016/j.biomaterials.2010.09.00410.1016/j.biomaterials.2010.09.004 ↗
11. 10.1002/jbm.a.3193910.1002/jbm.a.31939 ↗
12. 10.1189/jlb.060232510.1189/jlb.0602325 ↗
13. 10.1016/j.immuni.2014.06.00810.1016/j.immuni.2014.06.008 ↗
14. 10.1161/ATVBAHA.113.30016810.1161/ATVBAHA.113.300168 ↗
15. 10.4049/jimmunol.180.4.201110.4049/jimmunol.180.4.2011 ↗
16. 10.1016/j.cell.2010.03.01410.1016/j.cell.2010.03.014 ↗
17. Gollob J A. · Clin. Cancer Res. · 2000 · 6 · 1678
18. Hill H. · Cancer Res. · 2002 · 62 · 7254
19. 10.4049/jimmunol.178.3.135710.4049/jimmunol.178.3.1357 ↗
20. 10.1371/journal.pone.005401610.1371/journal.pone.0054016 ↗
21. 10.1016/j.biomaterials.2015.05.02810.1016/j.biomaterials.2015.05.028 ↗
22. 10.1038/nri166810.1038/nri1668 ↗
23. Morris S. M. · J. Nutr. · 2007 · 137 · 1602S10.1093/jn/137.6.1602S ↗
24. 10.1016/j.it.2004.09.01510.1016/j.it.2004.09.015 ↗
25. 10.1172/JCI2988110.1172/JCI29881 ↗
26. 10.1046/j.1365-3024.2001.00394.x10.1046/j.1365-3024.2001.00394.x ↗
27. 10.1093/jac/dkn00710.1093/jac/dkn007 ↗
28. 10.3389/fimmu.2014.0053210.3389/fimmu.2014.00532 ↗
29. 10.1016/j.ymgme.2008.02.00210.1016/j.ymgme.2008.02.002 ↗
30. Ferrante R. · J. Neurosci. · 2000 · 20 · 438910.1523/JNEUROSCI.20-12-04389.2000 ↗
31. 10.1249/MSS.0b013e3181fcee7d10.1249/MSS.0b013e3181fcee7d ↗
32. 10.1016/S0969-9961(02)00017-710.1016/S0969-9961(02)00017-7 ↗
33. 10.1021/bi972481d10.1021/bi972481d ↗
34. 10.1161/01.CIR.102.12.141410.1161/01.CIR.102.12.1414 ↗
35. 10.1002/cbf.180710.1002/cbf.1807 ↗
36. 10.1371/journal.pone.005287910.1371/journal.pone.0052879 ↗
37. 10.1073/pnas.95.16.956210.1073/pnas.95.16.9562 ↗
38. 10.1023/A:102498401306910.1023/A:1024984013069 ↗
39. 10.1038/3417810.1038/34178 ↗
40. 10.1016/S0014-5793(97)00925-310.1016/S0014-5793(97)00925-3 ↗
41. Motrán C. C. · J. Leukocyte Biol. · 2002 · 72 · 51210.1189/jlb.72.3.512 ↗
42. Levinson S. S. · Clin. Chem. · 1978 · 24 · 219910.1093/clinchem/24.12.2199 ↗
43. Bicerano J. · 200210.1201/9780203910115 ↗
44. 10.3389/fimmu.2014.0053210.3389/fimmu.2014.00532 ↗
45. 10.1046/j.1471-4159.2003.01695.x10.1046/j.1471-4159.2003.01695.x ↗
46. 10.1002/jbm.a.3516910.1002/jbm.a.35169 ↗
47. 10.1002/jbm.a.3456210.1002/jbm.a.34562 ↗
48. 10.1182/blood-2009-08-23671110.1182/blood-2009-08-236711 ↗
49. Docke F. R. W. · J. Immunol. · 1997 · 158 · 291110.4049/jimmunol.158.6.2911 ↗
50. 10.1084/jem.174.6.154910.1084/jem.174.6.1549 ↗
51. 10.1038/nri137210.1038/nri1372 ↗